An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B
Aim: to assess the safety and efficacy of telbivudine therapy in adult patients with CHB in Indonesia. Methods: the study design was prospective cohort study. Multicenter study of adult CHB patients requiring oral antiviral therapy in daily practice setting. All patients received 600 mg of telbivud...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2016-05-01
|
| Series: | Acta Medica Indonesiana |
| Online Access: | https://mail.actamedindones.org/index.php/ijim/article/view/62 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419230156423168 |
|---|---|
| author | Ali Sulaiman Laurentius A Lesmana Nafrialdi Nafrialdi Helyanna Helyanna |
| author_facet | Ali Sulaiman Laurentius A Lesmana Nafrialdi Nafrialdi Helyanna Helyanna |
| author_sort | Ali Sulaiman |
| collection | DOAJ |
| description |
Aim: to assess the safety and efficacy of telbivudine therapy in adult patients with CHB in Indonesia. Methods: the study design was prospective cohort study. Multicenter study of adult CHB patients requiring oral antiviral therapy in daily practice setting. All patients received 600 mg of telbivudine daily for one year. Recruitment and decision to start telbivudine therapy was based on clinical indication as assessed by the participating physicians. The primary end-point was patient safety (adverse event or serious adverse events); while the secondary end-points were HBeAg seroconversion, changes of serum HBV DNA levels and serum ALT normalization. Patients were assessed at week-24 and week-52 of treatment. Results: a total of 176 cases were eligible for analysis, comprising 104 (59.8%) HBeAg-positive and 70 (40.2%) HBeAg-negative patients. Adverse events were reported in 7 (4.0%) patients, most of them were mild. HBeAg loss and seroconversion rate was 28.8% and 14.14% at week-52 respectively. Undetectable HBV DNA (PCR negativity) was 51.8% at week-24 and 62.7% at week-52. Median HBV DNA levels were significantly reduced from baseline to week-24 and week-52 treatment (both p<0.001; Wilcoxon’s signed-rank test). Normalization of serum ALT activity occurred in 85 (73.28%) patients at week-52. Conclusion: Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients with chronic hepatitis B. Treatment efficacy in terms of HBeAg loss and seroconversion, changes of HBV DNA levels and serum ALT normalization were similar to previous reported studies.
Key words: Alanine aminotransferase, chronic hepatitis B, HBV DNA, oral antiviral treatment, telbivudine therapy.
|
| format | Article |
| id | doaj-art-a9c445c6c42c4c2eb0584653783c32af |
| institution | Kabale University |
| issn | 0125-9326 2338-2732 |
| language | English |
| publishDate | 2016-05-01 |
| publisher | Interna Publishing |
| record_format | Article |
| series | Acta Medica Indonesiana |
| spelling | doaj-art-a9c445c6c42c4c2eb0584653783c32af2025-08-20T03:32:11ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322016-05-01461An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis BAli Sulaiman0Laurentius A Lesmana1Nafrialdi Nafrialdi2Helyanna Helyanna3Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaDepartment of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaClinical Study Unit, Faculty of Medicine, Universitas Indonesia, Jakarta, IndonesiaPT. Novartis Indonesia, Jakarta, Indonesia Aim: to assess the safety and efficacy of telbivudine therapy in adult patients with CHB in Indonesia. Methods: the study design was prospective cohort study. Multicenter study of adult CHB patients requiring oral antiviral therapy in daily practice setting. All patients received 600 mg of telbivudine daily for one year. Recruitment and decision to start telbivudine therapy was based on clinical indication as assessed by the participating physicians. The primary end-point was patient safety (adverse event or serious adverse events); while the secondary end-points were HBeAg seroconversion, changes of serum HBV DNA levels and serum ALT normalization. Patients were assessed at week-24 and week-52 of treatment. Results: a total of 176 cases were eligible for analysis, comprising 104 (59.8%) HBeAg-positive and 70 (40.2%) HBeAg-negative patients. Adverse events were reported in 7 (4.0%) patients, most of them were mild. HBeAg loss and seroconversion rate was 28.8% and 14.14% at week-52 respectively. Undetectable HBV DNA (PCR negativity) was 51.8% at week-24 and 62.7% at week-52. Median HBV DNA levels were significantly reduced from baseline to week-24 and week-52 treatment (both p<0.001; Wilcoxon’s signed-rank test). Normalization of serum ALT activity occurred in 85 (73.28%) patients at week-52. Conclusion: Telbivudine therapy is generally safe and well tolerated among adult Indonesian patients with chronic hepatitis B. Treatment efficacy in terms of HBeAg loss and seroconversion, changes of HBV DNA levels and serum ALT normalization were similar to previous reported studies. Key words: Alanine aminotransferase, chronic hepatitis B, HBV DNA, oral antiviral treatment, telbivudine therapy. https://mail.actamedindones.org/index.php/ijim/article/view/62 |
| spellingShingle | Ali Sulaiman Laurentius A Lesmana Nafrialdi Nafrialdi Helyanna Helyanna An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B Acta Medica Indonesiana |
| title | An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B |
| title_full | An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B |
| title_fullStr | An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B |
| title_full_unstemmed | An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B |
| title_short | An Observational Study to Evaluate the Safety and Efficacy of Telbivudine in Adults with Chronic Hepatitis B |
| title_sort | observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis b |
| url | https://mail.actamedindones.org/index.php/ijim/article/view/62 |
| work_keys_str_mv | AT alisulaiman anobservationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT laurentiusalesmana anobservationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT nafrialdinafrialdi anobservationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT helyannahelyanna anobservationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT alisulaiman observationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT laurentiusalesmana observationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT nafrialdinafrialdi observationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb AT helyannahelyanna observationalstudytoevaluatethesafetyandefficacyoftelbivudineinadultswithchronichepatitisb |